15 November 2023 in Nature Communications
Plasmodium falciparum malaria drives immunoregulatory responses across multiple cell subsets, which protects from immunopathogenesis, but also hampers the development of effective anti-parasitic immunity. Understanding malaria induced tolerogenic responses in specific cell subsets may inform development of strategies to boost protective immunity during drug treatment and vaccination. Here, we analyse the immune landscape with single cell RNA sequencing during P. falciparum malaria. We identify cell type specific responses in sub-clustered major immune cell types. Malaria is associated with an increase in immunosuppressive monocytes, alongside NK and γδ T cells which up-regulate tolerogenic markers. IL-10-producing Tr1 CD4 T cells and IL-10-producing regulatory B cells are also induced. Type I interferon responses are identified across all cell types, suggesting Type I interferon signalling may be linked to induction of immunoregulatory networks during malaria. These findings provide insights into cell-specific and shared immunoregulatory changes during malaria and provide a data resource for further analysis.
26 November 2025 in Science Translational Medicine
Inhibiting the inflammatory response to malaria offers a promising strategy to improve clinical outcomes and overcome immunoregulatory barriers that hinder development of antiparasitic immunity. We conducted a double-blind, randomized, placebo-controlled trial assessing whether ruxolitinib, a Janus-activated kinase (JAK) 1/2 inhibitor, can reduce inflammatory responses and enhance antiparasitic immunity in malaria-naïve volunteers inoculated with blood-stage Plasmodium falciparum . Twenty participants were inoculated and, on day 8, randomized to receive artemether-lumefantrine with either ruxolitinib or placebo. Ninety days later, participants underwent a second inoculation. Ruxolitinib was safe and well tolerated; moreover, it attenuated inflammatory responses to the initial infection, with reduced posttreatment increases in C-reactive protein and markers of disease severity, including angiopoietin-2 and intercellular adhesion molecule-1. Ruxolitinib also enhanced immune memory after the second infection, with elevated human leukocyte antigen–DRA and 4-1BB, consistent with increased T cell activation. These data support the further evaluation of ruxolitinib as an adjunctive treatment to improve clinical outcomes and boost antiparasitic immunity in clinical malaria.
30 January 2026 in Nature Immunology
Dendritic cells (DCs) are pivotal for initiating adaptive immunity, a process triggered by the activation of DCs via pathogen products or damage. Immunization with sporozoites from Plasmodium leads to CD8 + T cell priming in a response initiated by collaboration between conventional type 1 DCs (cDC1s) and γδ T cells. Here we show that Vγ1 + γδ T cells have an initiating role by directly supplying interleukin-4 (IL-4). IL-4 and interferon-γ (IFNγ) synergize with CD4 + T cell-derived CD40L to induce IL-12 production by cDC1. Both IL-12 and IL-4 then directly signal responding CD8 + T cells and drive enhanced IL-12 receptor expression and expansion. This study shows how Vγ1 + γδ T cells can initiate CD8 + T cell immunity to Plasmodium and that responses to some pathogens require help from innate-like T cells to pass an initiation threshold and further amplify the response in a process underscored by IL-4 production.
30 September 2025 in Nature Communications
Age is a critical factor in immune responses to infection. In malaria, severe disease risk increases with age in non-immune individuals. Malaria severity is in part driven by inflammation, but mechanisms contributing to age-dependent disease risk are incompletely understood. We assessed inflammatory cytokines during malaria in non-immune children and adults, and innate cell responses in vitro to malaria parasites in naive children and adults. We show during malaria age is associated with increased inflammatory chemokines CCL2, CCL3, CXCL8, CXCL9, along with CRP, and IDO, which associate with symptoms. In naive individuals, classical monocyte and Vδ2+ γδ T cells from adults have higher inflammatory cytokine production, and transcriptional activation following stimulation with parasites. Classical monocyte responses in adults are dominated by CCL2, while in children increased IL10 and enrichment of IL10 signaling pathways is detected. Findings identify age-dependent cellular mechanisms that play crucial roles in driving inflammatory responses in malaria.
5 June 2026 in Research Square
FRFabian de Labastida Rivera
Fabian de Labastida Rivera
+18
Type I interferon (IFN) signalling promotes development of type 1 regulatory (Tr1) CD4+ T cells, which suppress inflammation but may limit protective immunity in malaria by constraining effector Th1 cells and antibody-promoting T follicular helper (Tfh) cells. We tested whether transiently blocking IFN-driven JAK/STAT signalling with ruxolitinib would reduce Tr1 cell development and enhance protective Th1 and Tfh cell responses. Using controlled human malaria infection, we investigated the impact of ruxolitinib on CD4+ T cell activation and antigen-specific immunity. Whole blood stimulation with IFNβ, IL-2, or PMA/Ionomycin revealed that ruxolitinib suppressed pSTAT1, pSTAT3, and pSTAT5 in CD4+ T cells following treatment. However, antigen-specific CD4+ T cell responses were preserved. Further, ruxolitinib enhanced recall CD4+ T cell responses during a second infection, with increased frequencies of antigen-specific Th1, Tfh, and Tr1 cell subsets. Transcriptional analysis revealed overlapping gene signatures and clonal sharing between Th1, Tfh and Tr1 cells. These findings show transient JAK inhibition can modulate development of Th1, Tfh and Tr1 cell subsets in malaria, suppressing inhibitory signalling while enhancing the magnitude and durability of the CD4+ T cell recall response following a second infection. Targeting IFN-driven Tr1 cell activity therefore represents a promising host-directed strategy to improve malaria immunity.